Available datapackage for study 'A Phase III Randomised, Double-blind Trial to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg Compared to Placebo, in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)'

The aim of the study is to investigate the safety and efficacy of empagliflozin versus
placebo on top of guideline-directed medical therapy in patients with heart failure with
reduced ejection fraction.

本研究旨在探讨在指南导向药物治疗（guideline-directed medical therapy）基础上，恩格列净（empagliflozin）与安慰剂相比，用于射血分数降低型心力衰竭（heart failure with reduced ejection fraction, HFrEF）患者的安全性与有效性。